A Phase 3 interventional study of pregabalin in Epilepsy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing pregabalin in Epilepsy — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsy.
Among the 12 studies testing pregabalin in Epilepsy, this one is the 9th largest by enrollment, is one of 2 that started in 2008, is one of 9 in phase 3, and was the 10th registered.
1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 12 studies testing pregabalin in Epilepsy is open now. The open studies under Epilepsy, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 112 (39%) set no upper age limit and 149 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2008.
This study's enrollment of 75 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 194 across the 12 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Epilepsy by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 18 (95%) have results posted.
Among the 19 studies in Epilepsy by Viatris Inc., this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2008, is one of 12 in phase 3, and was the 10th registered.
Viatris Inc.’s Epilepsy studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing pregabalin in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 19 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the long term safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy patients for the treatment of partial seizures. This is an extension study to a previous clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pregabalin
pregabalin
Seizure Frequency
Time frame: Baseline up to Week 28
Number of Participants With (All Causality) Adverse Events (AEs) and Serious Adverse Events (SAEs)
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category.
Time frame: Baseline up to Week 28
Number of Participants With Laboratory Test Values of Potential Clinical Importance
Pre-defined criteria were established for each laboratory test (hematology, blood chemistry and urinalysis) to define the values that would be identified as of potential clinical importance.
Time frame: Baseline up to Week 28
| Milestone | Pregabalin |
|---|---|
| Started | 75 |
| Enrolled, treated | 73 |
| Completed | 58 |
| Not completed | 17 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Unpecified | 2 |
| Withdrew: Enrolled, not treated | 2 |
No measurements were reported for this outcome.
Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Participants with multiple occurrences of an AE within a category were counted once within the category.
| Participants | Pregabalin |
|---|---|
| Non-serious AEs | 30 |
| Serious AEs (SAEs) | 3 |
Pre-defined criteria were established for each laboratory test (hematology, blood chemistry and urinalysis) to define the values that would be identified as of potential clinical importance.
| Participants | Pregabalin |
|---|---|
| Number of Participants With Laboratory Test Values of Potential Clinical Importance | 17 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 3/73 (4.1%) | 14/73 (19.2%) |
| Event | Pregabalin |
|---|---|
| ConvulsionNervous system disorders | 2/73 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/73 |
| Transient ischaemic attackNervous system disorders | 1/73 |
| Event | Pregabalin |
|---|---|
| NauseaGastrointestinal disorders | 4/73 |
| HeadacheNervous system disorders | 4/73 |
| Weight increasedInvestigations | 3/73 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/73 |
| ConvulsionNervous system disorders | 3/73 |
| Age, Customized(Participants) | Pregabalin |
|---|---|
| 18-44 years | 48 |
| 45-64 years | 23 |
| Greater than or equal to (≥) 65 years | 4 |
| Sex: Female, Male(Participants) | Pregabalin |
|---|---|
| Female | 38 |
| Male | 37 |
The record gives a start of Apr 2008, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →